LOG IN
SIGN UP
MARKET
CDMO
CDMO
Avid Bioservices
NASDAQ
Real-time Quotes | Nasdaq Last Sale
13.84
+1.09
+8.51%
Opening 14:55 05/27 EDT
OPEN
12.95
PREV CLOSE
12.75
HIGH
13.91
LOW
12.86
VOLUME
351.38K
TURNOVER
2.85M
52 WEEK HIGH
34.51
52 WEEK LOW
11.30
MARKET CAP
854.23M
P/E (TTM)
91.02
1D
5D
1M
3M
1Y
5Y
Those who invested in Avid Bioservices (NASDAQ:CDMO) three years ago are up 258%
The last three months have been tough on Avid Bioservices, Inc. ( NASDAQ:CDMO ) shareholders, who have seen the share...
Simply Wall St. · 05/16 16:43
Is Avid Bioservices, Inc. (NASDAQ:CDMO) A High Quality Stock To Own?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Simply Wall St. · 04/05 17:21
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology a...
GlobeNewswire · 03/16 20:05
Avid Bioservices's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Avid Bioservices (NASDAQ:CDMO) showed a loss in earnings since Q2, totaling $2.25 million. Sales, on the other hand, increased by 20.68% to $31.51 million during Q3.
Benzinga · 03/10 14:51
--Stephens Adjusts Avid Bioservices' Price Target to $28 from $31, Keeps Overweight Rating
MT Newswires · 03/09 10:04
--Craig-Hallum Lowers Price Target for Avid Bioservices to $30 From $35, Maintains Buy Rating
MT Newswires · 03/09 09:56
BRIEF-Avid Bioservices Reports Financial Results For Third Quarter Ended January 31, 2022 And Recent Developments
reuters.com · 03/08 23:06
Recap: Avid Bioservices Q3 Earnings
Avid Bioservices (NASDAQ:CDMO) reported its Q3 earnings results on Tuesday, March 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Avid Bioservices reported in-line EPS of $0.04 versus an estimate of $0.04.
Benzinga · 03/08 22:11
No Data
Learn about the latest financial forecast of CDMO. Analyze the recent business situations of Avid Bioservices through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDMO stock price target is 30.00 with a high estimate of 32.00 and a low estimate of 28.00.
Current 13.77
EPS
Actual
Estimate
-0.010.030.060.09
Institutional Holdings
Institutions: 232
Institutional Holdings: 67.30M
% Owned: 109.00%
Shares Outstanding: 61.74M
TypeInstitutionsShares
Increased
50
10.14M
New
51
3.61M
Decreased
62
4.11M
Sold Out
23
2.13M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Carleone
President/Chief Executive Officer/Director
Nicholas Green
Chief Financial Officer
Daniel Hart
Chief Operating Officer
Richard Richieri
Vice President/General Counsel/Secretary
Mark Ziebell
Other
Matthew Kwietniak
Director
Richard Hancock
Independent Director
Esther Alegria
Independent Director
Catherine Mackey
Independent Director
Gregory Sargen
Independent Director
Jeanne Thoma
No Data
No Data
About CDMO
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.
Webull offers kinds of Avid Bioservices Inc stock information, including NASDAQ:CDMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDMO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CDMO stock methods without spending real money on the virtual paper trading platform.